NEW YORK–(BUSINESS WIRE)–Aug. 26, 2003–It’s not an easy task. Leading the race as a biotech company not only requires competitive technology, it also requires strategic planning, operativepartnerships and plenty of capital. However, the challenges of running a biotech business today are more daunting than ever. High burn rates, limited access to capital, and layoffs are all symptomsof a typical business in the current environment. Access to that limited capital has now become the major talking point in an industry where large investments are required and long time lines are anorm. As this access becomes restricted, company management turn their attention to one thing — survival.
On Sept. 28-30, 2003, Strategic Research Institute will offer the only conference which focuses on financing and running a biotech business at the La Costa Resort & Spa, Carlsbad, Calif. An illustrious speaking faculty, including seasoned executives, active investors and prominent advisors will analyze, debate and explore the most effective survival strategies to deal with today’s financial crisis. Company executives will learn what it takes to enhance their worth in M&A deals, how to lower clinical trial costs without limiting research, affordable marketing and sales approaches, outsourcing resources, and alternative ways to raise more capital. Even investors will gain valuable insight into new investment structures and opportunities, risks and rewards of product vs. platform, plus partnering and exit options.
Featured speakers will include: Jean-Pierre Sommadossi, Ph.D., CEO of Idenix Pharmaceuticals; Linda Pullan, Ph.D., director of licensing, Amgen (NASDAQ: AMGN); Roy Cosan, vice president, Johnson & Johnson Development Corp.; Geoff Cooper, vice president, OSI Pharmaceuticals Inc.; Nola Masterson, venture partner, Techno Venture Management.
Decision-makers from the following firms will also be participating: A.M. Pappas & Associates; Academy Ventures; Acorda Therapeutics; Aderis Pharmaceuticals; Alta Partners; Ambit Biosciences; Amgen Inc.; Astral Inc.; Avanir Pharmaceuticals; Aventis Capital; BioMinerva Group; Biosector 2; California Institute of Technology; California Technology Ventures; CancerVax Corp.; Cano Biotechnology; CIBC World Markets; Cordova Ventures; Domain Associates; Favrille Inc.; Forward Ventures; Galileo Pharmaceuticals Inc.; Hamilton Apex Ventures; Heller Ehrman White & McAuliffe LLP; High Throughput Genomics; HOTventures; Idenix Pharmaceuticals Inc.; Intercell AG; Investor’s Business Daily; Johnson & Johnson Development Corp.; JPMorgan Partners; Kinetics Asset Management; L.E.K. Consulting; Lilly BioVentures; Manitoba Energy, Science and Technology; Market Ontario; Matrix Medical Consulting Inc.; Mayer, Brown, Rowe & Maw; MDS Inc.; Nanostream Inc.; OrbiMed Advisors LLC; OSI Pharmaceutical; Oxford Finance Corp.; Oxford Finance Corp.; Paul Capital Partners; Perceptive Informatics; Pierce Milwaukee; POSCO BioVentures; Rubicon Genomics Inc; San Diego Regional Technology Alliance; San Diego Tech Coast Angels; Sequenom; SG Cowen; Sofinnova Ventures; Structural GenomiX; Titan Pharmaceuticals; Tomlinson Zisko LLP; TVM Techno Venture Management; UC San Diego CONNECT; United States Securities & Exchange Commission.
For additional details, view the agenda at www.srinstitute.com/BoB2003 or contact Katherine Jimenez at 310-284-5939 or kjimenez@srinstitute.com. Mention key code DPR000615 when registering.
